pipette
ESEspañol

Multi-Lab Testing of Early Preclinical Discoveries Identifies Promising Treatments

P. Pellegrini, S. C. Rotter, M. Arroyo-Araujo, C. F. D. Carneiro, N. I. Drude, L. Martinez Gamboa, A. Banito, N. Bernhardt, A.-L. Boulesteix, F. Buttgereit, A. Dempfle, N. Duran-Hernandez, T. Gaber, M. Groettrup, B. Habelt, B. Haller, H. Hamza, S. Hettmer, A. Kliesow Remes, S. Kobold, M. Kochan, F. Konietschke, L. H. Lehmann, M. Löhning, A. Matzen, M. W. Meinhardt, H. Morrison, O. J. Müller, O. Planz, G. H. S. Richter, L. B. Riecken, S. K. Rosahl, K. Rubarth, K. Schmidt-Bleek, L. Schuler, A. Sharma, I. Skorodumov, R. Spanagel, I. Teichert-von Lüttichau

PreprintReal-world use

In the authors' words

A fundamental challenge in drug development is the frequent failure of early laboratory research to translate into clinical benefit. One promising solution is to confirm findings from exploratory single-laboratory studies across multiple laboratories before clinical testing. We investigated this approach following the conduct of preclinical multi-laboratory studies across different fields of medicine. For this, we evaluated effect sizes, experimental rigor, and a set of criteria to identify determinants of confirmation success. When tested under increased rigor, only a fraction of multi-laboratory studies confirmed the initial results. The underlying effect size reduction was associated with outcome-relevant experimental differences between exploratory and confirmatory stages. In summary, multi-laboratory studies proved highly informative and served as an effective filter for promising treatments.

Main resultLimitation the authors admit

Appeared: Saturday, September 26. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.09.21.753112